misc Flashcards
Parkinson’s mechanism
Loss of pigmented cells in substantia nigra - make and store dopamine
L-Dopa
1st line
Most effective for symptomatic relief
Usually for >65
DO NOT stop abruptly
Wearing off phenomenon: 50% of pts
Incr risk of hip fractures d/t homocysteine
Dopamine Agonists
No response to L-Dopa: Dopamine agonists ineffective
Bromocriptine (ergot derivative)
Pramipexole
Ropirinole
Apomoprhine
Rotigotine (patch)
Decrease milk production
Bromocriptine
Dopamine Agonist, ergot derivative
SEs: stroke, szs, AVH, hypotension, HTN, MI, GI bleed, pulmonary fibrosis, LFTs elevation
Pramipexole
Dopamine Agonist
Take to d/c: NMS
Renally adjusted, EPS, hypotension, rhabdo, AVH
CNS depression, hypotensive effects
Apomorphine
Intermittent or continuous infusion/injection
NO ZOFRAN! severe hypotension and loss of consciousness
Premed w/ trimethobenzamide
Test dose; monitor BP and Scr
SEs: AVH, sudden sleep, ortho hypotension/syncope/dizziness, MI, headache, rhinorrhea, edema
QT prolongation
MAO B Inhibitors
Early PD
Only modest symptomatic relief
Selegiline (more SEs?), Rasagiline (adjunct), Safinamide (adjunct)
Serotonin syndrome!
Caution: HTN, high tyramine foods, cardiovascular dz, etoh
COMT Inhibitors
Entacapone (prolong L dopa)
Tolcapone (prolong central L-Dopa breakdown. Red: hepatotoxicity, orthostatic hypotension)
Anticholinergics in Parkinsons
Artane (trihexyphenidyl) - most widely used
Cogentin (Benzotropine), may also inhibit dopamine reuptake
Propantheline (peripheral): drooling, urinary freq
Amantadine
Antiviral? with mild antiparkinson activity
MOA uncertain
More effective than anticholinergics
best as short term monotherapy
SE: livedo reticularis
Pimavanserin
Tx of hallucinations/delusions with parkisonian psychosis
Atypical antipsychotic, inverse agonist/antagonist activity at 5-HT2A/C
Alzheimers pathophys
Shortage of Ach
Neurofibrillary tangles - tau protein intracellular
neuritic plaques: extracellular amyloid beta
Alzheimers Dx
No bio marker
Thorough testing: Hx, MMSE, exclude other possible causes
Start Tx ASAP!
Donepezil
Reversible/non comp inhibition; ACHe inhibitor
Mild-mod AD
Titration Q 4-6 weeks
Amiodarone will increase level
B block: risk of AV block
NSAIDs: risk of GI bleed
Rivastigmine
Mild-mod AD
Inhibits AchE and butrylrylcholinesterase (sp) - broader efficacy
PO or Patch
DDI: bradycardia (b blcok), cholinergic effects (pyridostigmine), lowers sz threshhold
Galantamine
Mild-mod AD
Inhibits AchE and modulates nicotinic receptors: increase ACH release
Increased release of glutamate and serotonin
Bradycardia, cholinergic, lowers sz threshold
NMDA receptor antagonist
Memantine
Noncompetitive inhibitor, blocks glutamate from overstimulating NMDA receptors.
Moderate/severe AD
Acetazolamide, amiloride: reduce memantine excretion
Dextromethorphan: increase SEs
Red flags in HA
SNOOP
Systemic Neurologic Onset - new/sudden Other associated conditions Previous HA Hx - serverity
Migraine Abortive
NSAIDs APAP or w/ caffeine Triptans Ergots Gepants Ditans Antiemetics
Migraine preventative - established efficacy
probably effective
Candesartan (lisinopril) VPA Frovatriptan Metop,propan,timolol (atenolol, nadolol) Topamax (memantine, venlafaxine, amitriptyline)
others:
gabapentin, lamictal, verapamil/amlodipine, ami/nortriptyline
Hemicrania continua/paroxysmal hemicrania
Indomethacin
Cluster abortive
Triptans + O2
Cluster prevention
Verapamil!
Topamax
Glucocorticoids, lithium
Triptans
Inhibit release of vasoactive peptides –> vasoconstriction –> block pain pathways
Stimulate serotonin 1b/1d: inhibit dural nociception
Contraindications:
Cardiac: ischemic, vasospasm/angina, WPW, arrhythmias, peripheral vascular dz, uncontrolled HTN
Stroke: migraine/basilar/hemiplegic; ischemic bowel, cerebrovascular dz
SEs: vasospasm, MI, VT/VF, stroke, somnolence, N/V, CP/pressure/tightness, neck/jaw pain
Triptans general
Inhibit release of vasoactive peptides –> vasoconstriction –> block pain pathways
Stimulate serotonin 1b/1d: inhibit dural nociception
Contraindications:
Cardiac: ischemic, vasospasm/angina, WPW, arrhythmias, peripheral vascular dz, uncontrolled HTN
Stroke: migraine/basilar/hemiplegic; ischemic bowel, cerebrovascular dz
SEs: vasospasm, MI, VT/VF, stroke, somnolence, N/V, CP/pressure/tightness, neck/jaw pain
General caution w/: ergot deriviatives, MAO-AIs
Triptans specific
Sumatriptan: PO x1, may repeat in 2hours
(half life 2.5 hours)
SC: 1-6mg x1, may repeat in 2 hours. more efficacious than PO, fastest onset
Nasal: less SEs, unpleasant taste
Zolmitriptan: PO, Nasal spray, ODT
serotonergic effects
Naratriptan: slower onset, lower efficacy
Rizatriptan (Maxalt)
Caustion w/ propanolol! increases riza level by 70%
Almotriptan: contraindicated w/ ergots/triptans w/in 24 hours, strong serotonergic.
Eletriptan: most likely to produce short term and sustained benefit. 3A4 substrate, avoid within 72 hours after 3a4 inhibitors
Frovatriptan: slower onset, lower efficacy
Ergots
5HT 1b/d receptor agonists (like triptans)
Ergotamine: poor PO bioavailability (2%)
Avoid: CAD, PVD, HTN, hepatic/renal
DDI: avoid with 3a4 inhibitors: life threatening peripheral ischemia nad vasospasm
Dihydroergotamine
Alpha blocking: weaker arterial vasoconstrictor
More potent venoconstrictor and fewer SEs than ergotamine
No physical dependence or rebound headache
IV, IM, SC, NS
CGRP
Calcitonin gene related peptide
Most prevalent neuropeptide in trigeminovascular system
Alpha: cerebral
Beta: gut
very potent vasodilator in cerebral
Gepants
CGRP ANTAgonists. Prevent vasodilation.
Rimegepant: acute/proph
Atogepant: prophylaxis only
Urbogepant: acute only
CGRP
Calcitonin gene related peptide
Most prevalent neuropeptide in trigeminovascular system
Alpha: cerebral
Beta: gut
very potent vasodilator in cerebral
5HT1F Agonists
“Ditans” - lasmiditan
Inhibits trigeminal nerve firing. Acute HA only. 1 dose in 24 hours. 50-200mg PO x2
No driving w/in 8 hours
Caution with CNS depressants/ETOH/older
Migraine MABs
IV q3mo: eptinezumab, IgG1
SubQ Q mo: galcanezumab, IgG4
SubQ q month OR q3 months: Fremanezumab IgG2
^ acts as anti cgrp antibodies
IgG targets CGRP receptors: SubQ qmonth, Erenumab